104 related articles for article (PubMed ID: 38749268)
1. Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer.
Guan T; Zhang Y; Li S; Zhang W; Song Y; Li Y; He Y; Chen Y
Eur J Med Chem; 2024 Jun; 272():116494. PubMed ID: 38749268
[TBL] [Abstract][Full Text] [Related]
2. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
3. Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhao B; Liang Q; Ren H; Zhang X; Wu Y; Zhang K; Ma LY; Zheng YC; Liu HM
Eur J Med Chem; 2020 Apr; 192():112161. PubMed ID: 32155529
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone demethylase KDM5B for cancer treatment.
Fu YD; Huang MJ; Guo JW; You YZ; Liu HM; Huang LH; Yu B
Eur J Med Chem; 2020 Dec; 208():112760. PubMed ID: 32883639
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
6. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
[TBL] [Abstract][Full Text] [Related]
8. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
[TBL] [Abstract][Full Text] [Related]
9. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B; Kidder BL
Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
[TBL] [Abstract][Full Text] [Related]
10. Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt/β-catenin pathway.
Yan G; Li S; Yue M; Li C; Kang Z
Life Sci; 2021 Jan; 264():118726. PubMed ID: 33160990
[TBL] [Abstract][Full Text] [Related]
11. Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21.
Dai B; Hu Z; Huang H; Zhu G; Xiao Z; Wan W; Zhang P; Jia W; Zhang L
Biochem Biophys Res Commun; 2014 Nov; 454(1):221-7. PubMed ID: 25450384
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
13. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
[TBL] [Abstract][Full Text] [Related]
14. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
15. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.
Zhang SM; Cai WL; Liu X; Thakral D; Luo J; Chan LH; McGeary MK; Song E; Blenman KRM; Micevic G; Jessel S; Zhang Y; Yin M; Booth CJ; Jilaveanu LB; Damsky W; Sznol M; Kluger HM; Iwasaki A; Bosenberg MW; Yan Q
Nature; 2021 Oct; 598(7882):682-687. PubMed ID: 34671158
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
Brown LK; Kanagasabai T; Li G; Celada SI; Rumph JT; Adunyah SE; Stewart LV; Chen Z
Prostate; 2024 Jun; 84(9):877-887. PubMed ID: 38605532
[TBL] [Abstract][Full Text] [Related]
17. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
18. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
[TBL] [Abstract][Full Text] [Related]
19. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
[TBL] [Abstract][Full Text] [Related]
20. KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation.
Kidder BL; Hu G; Zhao K
Genome Biol; 2014 Feb; 15(2):R32. PubMed ID: 24495580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
